New “Bank” Adds Genomics Service to Patient Care
|
By HospiMedica International staff writers Posted on 06 Mar 2013 |
|
A new company is offering a “gene vault” service for doctors who need a better way to store, protect, and share genomic data.
Coriell Life Sciences (Camden, NJ, USA), a startup company that grew out of a partnership between the Coriell Institute for Medical Research (Camden, NJ, USA) and IBM (Armonk, NY, USA) is offering a service to facilitate sequencing a patient’s DNA—through existing sequencing companies such as Illumina (San Diego, CA, USA) or Ion Torrent—and store it in its so-called gene vault, and also act as the middleman between doctors and companies that offer interpretation services.
The cloud-based workflow could help doctors in different locations take advantage of expert interpretations anywhere, analyzing a patient’s genome for DNA variants linked to poor drug response at one point, and later on, for example, order another for variants linked to heart disease. The company will also use a board of scientific advisors to guide them as to the best interpretation programs available. Since keeping the genomic data secure is a key component of the venture, the data will be stored at IBM headquarters and would be available only to limited users. If a patient changes a health-care provider, the data will remain available for the next physician.
“The intent is that the doctor would order a test like any other diagnostic test they order today,” said Scott Megill, president of Coriell Life Sciences. “We will return the genetic result in the human readable form back to the electronic medical record so the doctor can read it and interpret it for the patient.”
“No one company is in position to interpret the entire genome for its meaning,” said Michael Christman, CEO of the Coriell Institute for Medical Research. “But by having one’s sequence in the gene vault, then the physician will be able to order interpretative engines, analogous to apps for the iPhone.”
Whole genome sequencing is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time. Almost any biological sample containing a full copy of the DNA can provide the material necessary for full genome sequencing. Such samples may include saliva, epithelial cells, bone marrow, or anything else that has DNA-containing cells. Because the sequence data that is produced can be quite large (for example, there are approximately six billion base pairs in each human diploid genome), genomic data is stored electronically and requires a large amount of computing power and storage capacity.
Related Links:
Coriell Institute for Medical Research
IBM
Illumina
Coriell Life Sciences (Camden, NJ, USA), a startup company that grew out of a partnership between the Coriell Institute for Medical Research (Camden, NJ, USA) and IBM (Armonk, NY, USA) is offering a service to facilitate sequencing a patient’s DNA—through existing sequencing companies such as Illumina (San Diego, CA, USA) or Ion Torrent—and store it in its so-called gene vault, and also act as the middleman between doctors and companies that offer interpretation services.
The cloud-based workflow could help doctors in different locations take advantage of expert interpretations anywhere, analyzing a patient’s genome for DNA variants linked to poor drug response at one point, and later on, for example, order another for variants linked to heart disease. The company will also use a board of scientific advisors to guide them as to the best interpretation programs available. Since keeping the genomic data secure is a key component of the venture, the data will be stored at IBM headquarters and would be available only to limited users. If a patient changes a health-care provider, the data will remain available for the next physician.
“The intent is that the doctor would order a test like any other diagnostic test they order today,” said Scott Megill, president of Coriell Life Sciences. “We will return the genetic result in the human readable form back to the electronic medical record so the doctor can read it and interpret it for the patient.”
“No one company is in position to interpret the entire genome for its meaning,” said Michael Christman, CEO of the Coriell Institute for Medical Research. “But by having one’s sequence in the gene vault, then the physician will be able to order interpretative engines, analogous to apps for the iPhone.”
Whole genome sequencing is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time. Almost any biological sample containing a full copy of the DNA can provide the material necessary for full genome sequencing. Such samples may include saliva, epithelial cells, bone marrow, or anything else that has DNA-containing cells. Because the sequence data that is produced can be quite large (for example, there are approximately six billion base pairs in each human diploid genome), genomic data is stored electronically and requires a large amount of computing power and storage capacity.
Related Links:
Coriell Institute for Medical Research
IBM
Illumina
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Pediatric Mask
Respire SOFT
New
Fetal Monitor
BT-380
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Critical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
